RxDoctor Payments DataLook up a doctor →

Craig Herrman, MD

Neurology · Indianapolis, INNPI 1750385332

Payments from drug & device makers

$7,761,079in general payments, 2019–2025

Across 1,178 payments — averaging $6588.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$5.5M
  • Genentech, Inc.$1.5M
  • TG Therapeutics, Inc.$549K
  • Adamas Pharmaceuticals, Inc.$118K
  • Janssen Research & Development, LLC$40K
  • Osmotica Pharmaceutical Corp.$30K
  • plus $50K from 54 others
$704in research payments, 2019–2025

Across 1 payment — averaging $703.81 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis Pharma AG$704

What the payments were for

  • Speaking & faculty fees$350%
  • Food & beverage$17,52598%
  • Education$3022%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis222$5,512,757
Genentech, Inc.104$1,460,731
TG Therapeutics, Inc.77$549,435
Adamas Pharmaceuticals, Inc.51$118,280
Janssen Research & Development, LLC23$40,213
Osmotica Pharmaceutical Corp.12$29,610
Biogen45$15,007
F. Hoffmann-la Roche AG1$14,797
EMD Serono, Inc.47$7,311
AbbVie(2 entities)198$4,295
Sanofi34$914
Vanda Pharmaceuticals Inc.24$870
Genentech USA, Inc.46$844
AstraZeneca21$652
Amgen(2 entities)18$419
Neurocrine Biosciences, Inc.16$333
Lundbeck LLC12$236
Banner Life Sciences, LLC11$235
Lilly USA, LLC18$230
UCB, Inc.10$221
CSL Behring11$215
Teva Pharmaceuticals USA, Inc.13$210
MDD US Operations, LLC11$185
Sunovion Pharmaceuticals Inc.16$185
Johnson & Johnson7$183
Eisai Inc.10$174
Acadia Pharmaceuticals Inc10$155
Argenx US, Inc.3$146
Amneal Pharmaceuticals LLC6$131
Pfizer8$128
SK Life Science, Inc.5$125
Jazz Pharmaceuticals Inc.4$115
Bristol Myers Squibb5$111
Takeda Pharmaceuticals U.S.A., Inc.5$108
Arbor Pharmaceuticals, Inc.2$107
Eli Lilly1$103
Alnylam Pharmaceuticals Inc.4$96
Acorda Therapeutics, Inc5$82
Merz Pharmaceuticals, LLC4$80
Livanova USA, Inc.5$79
Otsuka America Pharmaceutical, Inc.4$69
Avanir Pharmaceuticals, Inc.4$65
Saol Therapeutics Inc.4$61
Merz North America, Inc.3$54
Bausch Health US, LLC2$49
Harmony Biosciences LLC2$48
Catalyst Pharmaceuticals, Inc.3$47
Supernus Pharmaceuticals, Inc.2$46
Cycle Pharmaceuticals Inc2$44
Greenwich Biosciences, Inc.3$43
Mallinckrodt Hospital Products Inc.2$41
Sanofi-aventis U.S. LLC2$38
Inspire Medical Systems, Inc.1$37
Medtronic2$36
Axsome Therapeutics, Inc.2$36
Ipsen Biopharmaceuticals, Inc2$33
Octapharma USA, Inc.2$32
Springworks Therapeutics, Inc.1$26
ANI Pharmaceuticals, Inc.1$25
Akcea Therapeutics, Inc.1$25

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,761,079 in reported general payments places this provider in the 95th percentile of 308 neurology providers in Indiana.

See all neurology providers in Indiana

Medicare billing

Part B allowed, 2024
$1,469,608
Medicare patients
672
Services billed
63,316

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab59$596,073
VumerityDiroximel Fumarate13$159,310
CopaxoneGlatiramer Acetate23$131,449
NuedextaDextromethorphan Hbr/Quinidine31$65,630
Teriflunomide57$33,872
AptiomEslicarbazepine Acetate16$27,327
Aimovig AutoinjectorErenumab-Aooe33$26,653
Glatiramer Acetate13$24,603
BotoxOnabotulinumtoxina16$19,540
Baclofen112$9,743
Lacosamide23$6,437
Dalfampridine ErDalfampridine33$3,927
Modafinil22$1,978
Tolterodine Tartrate ErTolterodine Tartrate17$1,891
Lamotrigine ErLamotrigine11$1,832

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenVumerity$15,007$159,31013 claims
Teva Pharmaceuticals USA, Inc.Copaxone, Acyclovir$210$131,52637 claims
Avanir Pharmaceuticals, Inc.Nuedexta$65$65,63031 claims
Sunovion Pharmaceuticals Inc.Aptiom$185$27,32716 claims
AbbVieBotox$4,295$19,54016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 308 neurology providers in Indiana.

Other neurology in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →